Teva discontinues Phase III chronic cluster headache trial of fremanezumab

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) discontinued a Phase III trial of fremanezumab (TEV-48125) to prevent chronic cluster headache based on a prespecified futility analysis. The company said a Phase III trial of the mAb targeting the calcitonin gene-related peptide (CGRP) ligand to prevent episodic cluster headache will continue as planned.

In the double-blind, international chronic cluster headache trial, a prespecified futility analysis showed that fremanezumab was unlikely to meet the primary endpoint of reducing monthly mean cluster headache attacks over the 12-week treatment period vs. placebo...